Selective Tyk2 Inhibitors for IBD and Psoriasis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Developing selective Tyk2 inhibitors that avoid inhibiting Jak2 is challenging due to the high sequence homology between Jak family kinase members, which is problematic as Jak2 inhibition leads to hematologic toxicities, and existing treatments for inflammatory bowel disease and psoriasis have limitations.
Innovation Solution
Compounds of Formula (I) and their pharmaceutically acceptable salts, which potently and selectively inhibit Tyk2 with high selectivity over Jak2, are developed for treating inflammatory bowel disease and psoriasis by administering an effective amount to a subject in need.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Jak2 inhibition is used to treat inflammatory diseases, then anti-inflammatory effect is achieved, but hematologic toxicities occur
Solution Approach 1:
The invention segments the Jak family kinase inhibition by developing compounds that selectively inhibit Tyk2 while sparing Jak2. This is achieved through specific molecular结构设计 that targets Tyk2's unique structural features, allowing separation of the anti-inflammatory effect (mediated by Tyk2 inhibition) from the hematologic toxicity (mediated by Jak2 inhibition).
Solution Approach 2:
The invention applies local quality by designing inhibitors with specific molecular characteristics that confer selectivity for Tyk2 over Jak2. The compounds possess particular structural features (such as specific substituent patterns on the pyrimidine core) that match Tyk2's binding pocket geometry and chemical properties, enabling selective binding and inhibition without affecting Jak2.
2Object-affected harmful factors
If selective Tyk2 inhibitors are developed, then hematologic toxicities are reduced, but development difficulty increases due to high sequence homology
Solution Approach 1:
The invention employs parameter changes by systematically varying molecular parameters of the inhibitor compounds to achieve selectivity. This includes changing substituent types, positions, and properties on the pyrimidine core structure, as well as modifying the linker and warhead groups. These parameter variations allow optimization of binding affinity for Tyk2 while reducing affinity for Jak2, overcoming the challenge of high sequence homology.
3Reliability
If existing treatments (anti-IL-12/23 antibodies) are used, then inflammatory symptoms are controlled, but treatment limitations persist
Solution Approach 1:
The invention substitutes the mechanism of action from antibody-based blockade (mechanical blocking of cytokine-receptor interaction) to small molecule kinase inhibition (chemical interference with enzymatic phosphorylation activity). This substitution provides advantages in terms of oral bioavailability, tissue penetration, and ability to block downstream signaling regardless of cytokine variability, thereby overcoming treatment limitations of existing antibody therapies.
Data Source
AI summary
Disclosed herein are compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4a, R4b, X1, X2, X3, X4, X5, nad n are as defined herein, pharmaeceutical compositions 2C X5, and n are as defined herein, pharmaceutical compositions comprising same, and methods of preparation and use.